Boston Scientific Inc. (BSX): Today's Featured Health Services Laggard

Editor's Note: TheStreet ratings do not represent the views of TheStreet's staff or its contributors. Ratings are established by computer based on metrics for performance (which includes growth, stock performance, efficiency and valuation) and risk (volatility and solvency). Companies with poor cash flow or high debt levels tend to earn lower ratings in our model.

Boston Scientific ( BSX) pushed the Health Services industry lower today making it today's featured Health Services laggard. The industry as a whole was unchanged today. By the end of trading, Boston Scientific fell 14 cents (-1.8%) to $7.65 on average volume. Throughout the day, 21.9 million shares of Boston Scientific exchanged hands as compared to its average daily volume of 22 million shares. The stock ranged in price between $7.65-$7.91 after having opened the day at $7.82 as compared to the previous trading day's close of $7.79. Other companies within the Health Services industry that declined today were: Integra LifeSciences Holdings ( IART), down 11.1%, Sunshine Heart ( SSH), down 10.5%, Uroplasty ( UPI), down 9.4%, and American Shared Hospital ( AMS), down 8.2%.
  • EXCLUSIVE OFFER: Jim Cramer's Protégé, Dave Peltier, only buys Stocks Under $10 that he thinks could potentially double. See what he's trading today with a 14-day FREE pass.

Boston Scientific Corporation develops, manufactures, and markets medical devices used in various interventional medical specialties worldwide. Boston Scientific has a market cap of $10.56 billion and is part of the health care sector. Shares are up 36% year to date as of the close of trading on Wednesday. Currently there are four analysts that rate Boston Scientific a buy, no analysts rate it a sell, and 13 rate it a hold.

TheStreet Ratings rates Boston Scientific as a sell. The company's weaknesses can be seen in multiple areas, such as its deteriorating net income, disappointing return on equity and feeble growth in its earnings per share.

On the positive front, Biolase ( BIOL), up 13.3%, ImmunoCellular Therapeutics ( IMUC), up 6.2%, Grifols ( GRFS), up 5.9%, and Enzo Biochem ( ENZ), up 5.8%, were all gainers within the health services industry with Intuitive Surgical ( ISRG) being today's featured health services industry leader.

For investors not wanting singular stock exposure, ETFs may be of interest. Investors who are bullish on the health services industry could consider Health Care Select Sector SPDR ( XLV) while those bearish on the health services industry could consider ProShares Ultra Short Health Care ( RXD).

Exclusive Offer: Jim Cramer's 'go-to' small/mid-cap guru Bryan Ashenberg only buys stocks he thinks could return 50-100% See his top picks for 14-days FREE.